|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net of allowance for credit losses of $0 and $0, respectively | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Patents, net of accumulated amortization of $3,185,585 and $3,048,750, respectively | ||||||||||||||||||||
| Patents, net of accumulated amortization of $6,004,656 and $4,856,737, respectively | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable and accrued liabilities ($10,000 and $10,000 due to related parties, respectively) | ||||||||||||||||||||
| Loans payable | ||||||||||||||||||||
| Funding liability | ||||||||||||||||||||
| Loan payable - related party | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Non-current liabilities | ||||||||||||||||||||
| Loan payable – SBA | ||||||||||||||||||||
| Purchase price of patents | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ deficit: | ||||||||||||||||||||
| Common stock, par value $0.00003 per share; authorized 30,000,000 at June 30, 2026 and December 31, 2025; 5,331,973 shares issued and outstanding at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Quest Patent Research Corporation stockholders’ deficit | ||||||||||||||||||||
| Non-controlling interest in subsidiary | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities and stockholders’ deficit | ||||||||||||||||||||
Loading...
